Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jing Wu, Zhaohua Zhu, Qinghong Yu & Changhai Ding. (2019) Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials. Expert Opinion on Investigational Drugs 28:12, pages 1113-1123.
Read now
Read now
Paul Glossop, Gavin Whitlock & Karl Gibson. (2015) Small-molecule anti-inflammatory drug compositions for the treatment of asthma: a patent review (2013 – 2014). Expert Opinion on Therapeutic Patents 25:7, pages 743-754.
Read now
Read now
Peter Norman. (2014) Respivert’s multikinase inhibitors, an evaluation of WO2014033446 to WO2014033449. Expert Opinion on Therapeutic Patents 24:12, pages 1397-1407.
Read now
Read now
Articles from other publishers (23)
Precious Ayorinde Akinnusi, Samuel Olawale Olubode, Ayomide Oluwadarasimi Adebesin, Adebowale Abiodun Alade, Victor Chinedu Nwoke & Sidiqat Adamson Shodehinde. (2023) Optimal molecular binding data and pharmacokinetic profiles of novel potential triple-action inhibitors of chymase, spleen tyrosine kinase, and prostaglandin D2 receptor in the treatment of asthma. Journal of Genetic Engineering and Biotechnology 21:1.
Crossref
Crossref
Rakesh Sahu, Kamal Shah, Yash Gautam & Kaushilya Sahu. (2023) Pyrazine Moiety: Recent Developments in Cancer Treatment. Current Organic Chemistry 27:10, pages 821-843.
Crossref
Crossref
Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han & Chenzhong Liao. (2021) Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. Journal of Medicinal Chemistry 64:3, pages 1283-1345.
Crossref
Crossref
Adam G. Schwaid & Kerrie B. Spencer. (2020) Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space. Journal of Medicinal Chemistry 64:1, pages 101-122.
Crossref
Crossref
Bernard Barlaam, Scott Boiko, Scott Boyd, Hannah Dry, Lakshmaiah Gingipalli, Timothy Ikeda, Tony Johnson, Sameer Kawatkar, Olivier Lorthioir, Andy Pike, Hannah Pollard, Jon Read, Qibin Su, Haiyun Wang, Huimin Wang, Lianghe Wang, Peng Wang & Scott D. Edmondson. (2020) Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors. Bioorganic & Medicinal Chemistry Letters 30:22, pages 127523.
Crossref
Crossref
Sameer P. Kawatkar, Bernard Barlaam, Paul Kemmitt, Iain Simpson, David Watson, Peng Wang, Scott Lamont, Qibin Su, Scott Boiko, Timothy Ikeda, Joe Patel, Andy Pike, Hannah Pollard, Jon Read, Ujjal Sarkar, Haiyun Wang, Quanshan Wen, Zhiyuan Yan, James E. Dowling, Hannah Dry & Scott D. Edmondson. (2020) Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase. Bioorganic & Medicinal Chemistry Letters 30:18, pages 127393.
Crossref
Crossref
Peter Blomgren, Jayaraman Chandrasekhar, Julie A. Di Paolo, Wanchi Fung, Guoju Geng, Carmen Ip, Randall Jones, Jeffrey E. Kropf, Eric B. Lansdon, Seung Lee, Jennifer R. Lo, Scott A. Mitchell, Bernard Murray, Chris Pohlmeyer, Aaron Schmitt, Kimberly Suekawa-Pirrone, Sarah Wise, Jin-Ming Xiong, Jianjun Xu, Helen Yu, Zhongdong Zhao & Kevin S. Currie. (2020) Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases. ACS Medicinal Chemistry Letters 11:4, pages 506-513.
Crossref
Crossref
Cheng Wang, Xin Wang, Yao Li, Tianqi Wang, Zhi Huang, Zhongxiang Qin, Shengyong Yang, Rong Xiang & Yan Fan. (2020) Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor. Bioorganic Chemistry 95, pages 103547.
Crossref
Crossref
Ananta Ganjoo & Chetti Prabhakar. (2019) In silico structural anatomization of spleen tyrosine kinase inhibitors: Pharmacophore modeling, 3D QSAR analysis and molecular docking studies. Journal of Molecular Structure 1189, pages 102-111.
Crossref
Crossref
My S. Mansueto, Abigail Reens, Larissa Rakhilina, An Chi, Bo-Sheng Pan & J. Richard Miller. (2019) A reevaluation of the spleen tyrosine kinase (SYK) activation mechanism. Journal of Biological Chemistry 294:19, pages 7658-7668.
Crossref
Crossref
Tamás Németh, Oana Virtic, Cassian Sitaru & Attila Mócsai. (2017) The Syk Tyrosine Kinase Is Required for Skin Inflammation in an In Vivo Mouse Model of Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology 137:10, pages 2131-2139.
Crossref
Crossref
C. Tabeling, J. Herbert, A. C. Hocke, D. J. Lamb, S. L. Wollin, K. J. Erb, E. Boiarina, H. Movassagh, J. Scheffel, J. M. Doehn, S. Hippenstiel, M. Maurer, A. S. Gounni, W. M. Kuebler, N. Suttorp & M. Witzenrath. (2017) Spleen tyrosine kinase inhibition blocks airway constriction and protects from Th2-induced airway inflammation and remodeling. Allergy 72:7, pages 1061-1072.
Crossref
Crossref
Xavier Sisquella, Thomas Nebl, Jennifer K Thompson, Lachlan Whitehead, Brian M Malpede, Nichole D Salinas, Kelly Rogers, Niraj H Tolia, Andrea Fleig, Joseph O’Neill, Wai-Hong Tham, F David Horgen & Alan F Cowman. (2017) Plasmodium falciparum ligand binding to erythrocytes induce alterations in deformability essential for invasion. eLife 6.
Crossref
Crossref
Betty Lam, Yasuyoshi Arikawa, Joshua Cramlett, Qing Dong, Ron de Jong, Victoria Feher, Charles E. Grimshaw, Pamela J. Farrell, Isaac D. Hoffman, Andy Jennings, Benjamin Jones, Jennifer Matuszkiewicz, Joanne Miura, Hiroshi Miyake, Srinivasa Reddy Natala, Lihong Shi, Masashi Takahashi, Ewan Taylor, Corey Wyrick, Jason Yano, Jonathan Zalevsky & Zhe Nie. (2016) Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK). Bioorganic & Medicinal Chemistry Letters 26:24, pages 5947-5950.
Crossref
Crossref
Neil S. Garton, Michael D. Barker, Rob P. Davis, Clement Douault, Edward Hooper-Greenhill, Emma Jones, Huw D. Lewis, John Liddle, Dave Lugo, Scott McCleary, Alex G.S. Preston, Cesar Ramirez-Molina, Margarete Neu, Tracy J. Shipley, Don O. Somers, Robert J. Watson & David M. Wilson. (2016) Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors. Bioorganic & Medicinal Chemistry Letters 26:19, pages 4606-4612.
Crossref
Crossref
Peter J. Barnes. (2016) Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. Pharmacological Reviews 68:3, pages 788-815.
Crossref
Crossref
Virginie Y. Martiny, François Martz, Edithe Selwa & Bogdan I. Iorga. (2015) Blind Pose Prediction, Scoring, and Affinity Ranking of the CSAR 2014 Dataset. Journal of Chemical Information and Modeling 56:6, pages 996-1003.
Crossref
Crossref
Terry King-Wing Ma, Stephen P. McAdoo & Frederick Wai-Keung Tam. (2016) Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease. Nephron 133:4, pages 261-269.
Crossref
Crossref
Y. Matsuda, X. Wang, H. Oishi, Z. Guan, M. Saito, M. Liu, S. Keshavjee & C.‐W. Chow. (2015) Spleen Tyrosine Kinase Modulates Fibrous Airway Obliteration and Associated Lymphoid Neogenesis After Transplantation. American Journal of Transplantation 16:1, pages 342-352.
Crossref
Crossref
Roberta Fenoglio, Fernando Fervenza & Dario Roccatello. 2016. Connective Tissue Disease. Connective Tissue Disease
239
261
.
Gebhard Thoma, Siem Veenstra, Ross Strang, Joachim Blanz, Eric Vangrevelinghe, Jörg Berghausen, Christian C. Lee & Hans-Günter Zerwes. (2015) Orally bioavailable Syk inhibitors with activity in a rat PK/PD model. Bioorganic & Medicinal Chemistry Letters 25:20, pages 4642-4647.
Crossref
Crossref
Gebhard Thoma, Alexander B. Smith, Maurice J. van Eis, Eric Vangrevelinghe, Joachim Blanz, Reiner Aichholz, Amanda Littlewood-Evans, Christian C. Lee, Hong Liu & Hans-Günter Zerwes. (2015) Discovery and Profiling of a Selective and Efficacious Syk Inhibitor. Journal of Medicinal Chemistry 58:4, pages 1950-1963.
Crossref
Crossref
Matthew C Lucas & Seng-Lai Tan. (2014) Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?. Future Medicinal Chemistry 6:16, pages 1811-1827.
Crossref
Crossref